Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

JUNO DIAGNOSTICS TO PARTICIPATE AT PRECISION MEDICINE WORLD CONFERENCE SILICON VALLEY, 2023


SAN DIEGO, Jan. 25, 2023 /PRNewswire/ -- Juno Diagnosticstm (JunoDxtm), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced it will participate at the Precision Medicine World Conference (PMWC), held January 25-27, 2023, in Santa Clara, CA.

Dr. Mathias Ehrich, Chief Medical Officer and co-founder at Juno Diagnostics, will present a company overview on Friday, January 27th, at 10:00 am PT. In addition, Todd Whitson, Executive President of Business Development and Commercial Operations, will also be attending the conference and will be available for meetings throughout the event.

About Juno Diagnosticstm

Juno Diagnosticstm is a category-defining health company bringing vital prenatal health information to patients by combining access, affordability, and transparency. The Company's lead product, Juno Hazeltm, is a non-invasive prenatal screening (NIPS) solution that simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS. 

For more information, visit www.junodx.com and engage with us on LinkedIn.

Investor and Media Contact:

Amy Conrad
Juniper Point
[email protected]
858-366-3243

SOURCE Juno Diagnostics


These press releases may also interest you

at 09:00
Dental Care Acworth is thrilled to utilize this remarkable innovation and offer patients unbiased, objective and standardized dental care that they know they can trust. The AI solutions Pearl delivers can assist dental...

at 09:00
Tolland Hill Family Dental is thrilled to announce the addition of Dr. Conway Ma to its esteemed team of dental professionals. Tolland Hill Family Dental offers a wide range of services, catering to patients of all ages. From a child's first dental...

at 09:00
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a...

at 09:00
Arbele, a clinical-stage biotechnology company focused...

at 08:53
Alera Health, a leader in population health management integrating behavioral healthcare, is proud to announce its recognition as one of the Great Employers to Work for in North Carolina by Best Companies Group. The 2024 Great Employers to Work for...



News published on and distributed by: